{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:41:41Z","timestamp":1761028901537,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12350-018-01534-6","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T14:42:35Z","timestamp":1543329755000},"page":"2011-2016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing severity of cardiac sarcoid: Is SUV the answer?"],"prefix":"10.1016","volume":"27","author":[{"given":"Stephanie","family":"Montalto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Better","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-018-01534-6_bib1","first-page":"1","article-title":"Cardiac sarcoidosis: An expert review for the chest physician","volume":"3","author":"Ho","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"10.1007\/s12350-018-01534-6_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.amjcard.2017.05.060","article-title":"Reliability of cardiovascular risk calculators to estimate accurately the risk of cardiovascular disease in patients with sarcoidosis","volume":"120","author":"Ungprasert","year":"2017","journal-title":"AM K Cardiol"},{"key":"10.1007\/s12350-018-01534-6_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.113.000867","article-title":"Evaluation of known or suspected cardiac sarcoidosis","volume":"9","author":"Blankstein","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-018-01534-6_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2015.03.175","article-title":"Electrocardiographic abnormalities and risk of developing cardiac events in extracardiac sarcoidosis","volume":"189","author":"Nagao","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1007\/s12350-018-01534-6_bib5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-018-01534-6_bib6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12350-016-0658-1","article-title":"Isolated cardiac sarcoidosis: A focused review of an under-recognized entity","volume":"25","author":"Okada","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-018-01534-6_bib7","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-018-01534-6_bib8","doi-asserted-by":"crossref","first-page":"e9088","DOI":"10.1371\/journal.pone.0009088","article-title":"Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations","volume":"5","author":"Sweiss","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1007\/s12350-018-01534-6_bib9","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1007\/s12350-018-01534-6_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/5584_2015_193","article-title":"Polymorphism of FCGR2A, FCGR2C, and FCGR3B genes in the pathogenesis of sarcoidosis","volume":"905","author":"Typiak","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1007\/s12350-018-01534-6_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.110.958322","article-title":"Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: Role of programmed ventricular stimulation","volume":"4","author":"Mehta","year":"2011","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"10.1007\/s12350-018-01534-6_bib12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.amjcard.2005.03.059","article-title":"Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis","volume":"96","author":"Aizer","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-018-01534-6_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/echo.13281","article-title":"Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction","volume":"33","author":"Murtagh","year":"2016","journal-title":"Echocardiography."},{"key":"10.1007\/s12350-018-01534-6_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","article-title":"Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis","volume":"63","author":"Blankstein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-018-01534-6_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCEP.113.000156","article-title":"Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias","volume":"7","author":"Crawford","year":"2014","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"10.1007\/s12350-018-01534-6_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jcmg.2016.11.019","article-title":"Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis","volume":"10","author":"Kouranos","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-018-01534-6_bib17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/ehjci\/jex340","article-title":"Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging in cardiac sarcoidosis","volume":"19","author":"Wicks","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"10.1007\/s12350-018-01534-6_bib18","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12350-017-0978-9","article-title":"Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring","volume":"24","author":"Chareonthaitawee","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-018-01534-6_bib19","unstructured":"Flores R, Flaherty K, Jin Z et al. The prognostic value of quantifying and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol."},{"key":"10.1007\/s12350-018-01534-6_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCIMAGING.112.000289","article-title":"Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography?","volume":"6","author":"McArdle","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-018-01534-6_bib21","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00259-018-4001-8","article-title":"Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET\/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia","volume":"45","author":"Muser","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1007\/s12350-018-01534-6_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12350-016-0490-7","article-title":"The response of FDG uptake to immunosuppressive treatment on FDG PET\/CT imaging for cardiac sarcoidosis","volume":"24","author":"Ahmadian","year":"2017","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-018-01534-6_bib23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","article-title":"Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis","volume":"21","author":"Ahmadian","year":"2014","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-018-01534-6_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12350-016-0682-1","article-title":"The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis","volume":"24","author":"Lee","year":"2017","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-018-01534-6_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","article-title":"Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis","volume":"21","author":"Osborne","year":"2014","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-018-01534-6_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jcmg.2017.04.020","article-title":"Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis","volume":"11","author":"Sperry","year":"2018","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1007\/s12350-018-01534-6_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13550-017-0315-y","article-title":"Semi-quantitative metabolic values on FDG PET\/CT as predictor of treatment course","volume":"7","author":"Ishiyama","year":"2017","journal-title":"EJNMMI Res."},{"key":"10.1007\/s12350-018-01534-6_bib28","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1007\/s00330-017-4824-x","article-title":"Delayed contrast-enhanced computed tomography in patients with known or suspected cardiac sarcoidosis: A feasibility study","volume":"27","author":"Aikawa","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1007\/s12350-018-01534-6_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-016-0207-6","article-title":"A dual tracer (68)Ga-DOTANOC PET\/CT and (18)F-FDG PET\/CT pilot study for detection of cardiac sarcoidosis","volume":"6","author":"Gormsen","year":"2016","journal-title":"EJNMMI Res."}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-018-01534-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12350-018-01534-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123020706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123020706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-018-01534-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:08:28Z","timestamp":1761026908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123020706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1071358123020706"],"URL":"https:\/\/doi.org\/10.1007\/s12350-018-01534-6","relation":{},"ISSN":["1071-3581"],"issn-type":[{"type":"print","value":"1071-3581"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing severity of cardiac sarcoid: Is SUV the answer?","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-018-01534-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}